Xlife Sciences AG Logo

Xlife Sciences AG

A life sciences incubator commercializing early-stage academic research for healthcare markets.

XLS | SW

Overview

Corporate Details

ISIN(s):
CH0461929603 (+1 more)
LEI:
984500AH590BE88BB517
Country:
Switzerland
Address:
Talacker 35, 8001 Zürich
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Xlife Sciences AG is a Swiss company that operates as a life sciences incubator and accelerator. It focuses on the value development and commercialization of promising, early-stage research projects sourced from universities and other research institutions. The company's mission is to bridge the gap between academic research and healthcare markets by advancing solutions for high unmet medical needs. Xlife Sciences concentrates its investments and development efforts across four key pillars: technology platforms, biotechnologies/therapies, medical technology (healthtech), and the application of artificial intelligence in digital health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-23 07:00
Report Publication Announcement
Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AGs NASDAQ Lis…
English 7.0 KB
2025-09-23 02:00
Earnings Release
Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Li…
English 9.5 KB
2025-09-23 02:00
Earnings Release
Xlife Sciences AG Halbjahresbericht 2025: Fokus auf NASDAQ-Listing der VERAXA B…
German 13.3 KB
2025-07-17 07:00
Registration Form
Xlife Sciences AGs Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward …
English 12.6 KB
2025-07-17 02:00
M&A Activity
Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward…
English 15.5 KB
2025-07-17 02:00
Registration Form
Portfoliounternehmen der Xlife Sciences AG, VERAXA Biotech AG, erreicht wichtig…
German 16.4 KB
2025-06-24 18:00
Post-Annual General Meeting Information
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
English 6.1 KB
2025-06-24 02:00
Post-Annual General Meeting Information
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
English 8.2 KB
2025-06-24 02:00
Post-Annual General Meeting Information
Xlife Sciences AG: Erfolgreiche Generalversammlung und Wachstumsaussichten in 2…
German 8.5 KB
2025-06-16 16:00
Regulatory News Service
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and Onc…
English 9.8 KB
2025-06-16 02:00
Regulatory News Service
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and Onc…
English 12.3 KB
2025-06-16 02:00
M&A Activity
Strategische Zusammenarbeit zwischen Xlife Sciences AG, Huraypositive Corp. und…
German 13.4 KB
2025-06-13 17:42
M&A Activity
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Acc…
English 9.0 KB
2025-06-13 02:00
M&A Activity
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Acc…
English 11.4 KB
2025-06-13 02:00
Regulatory News Service
Strategische Allianz zwischen Xlife Sciences AG, JIPYONG LLC und JIPYONG IP sol…
German 12.9 KB

Automate Your Workflow. Get a real-time feed of all Xlife Sciences AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Xlife Sciences AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-15 N/A Executive member Buy None 6,000.00 CHF
2022-06-15 N/A Executive member Buy None 3,000.00 CHF
2022-06-14 N/A Executive member Buy None 15,500.00 CHF
2022-06-10 N/A Executive member Buy None 6,728.90 CHF
2022-06-07 N/A Executive member Buy None 34,800.00 CHF
2022-06-03 N/A Executive member Buy None 3,540.00 CHF
2022-05-24 N/A Executive member Buy None 3,400.00 CHF
2022-05-17 N/A Executive member Buy None 10,794.20 CHF
2022-05-13 N/A Executive member Buy None 3,690.00 CHF
2022-05-10 N/A Executive member Buy None 1,935.00 CHF

Peer Companies

Company Country Ticker View
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany NMI
Alten Logo
Global engineering and IT consulting for digital transformation in industry and telecom sectors.
France ATE
Amoéba Logo
Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.
France ALMIB
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom APTA
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel ARAN
ARIX BIOSCIENCE PLC Logo United Kingdom ARIX
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden ASAP

Talk to a Data Expert

Have a question? We'll get back to you promptly.